Real-World Infliximab Pharmacokinetic Study Informs Record-Embedded Dashboard to Guide Precision Dosin Disease

Clinical Pharmacology and Therapeutics

109, 1639-1647

DOI: 10.1002/cpt.2148

Citation Report

#	Article	IF	Citations
1	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. Frontiers in Pediatrics, 2021, 9, 634739.	2.4	13
2	Population Pharmacokinetics of Infliximab in Children With Juvenile Idiopathic Arthritis. Therapeutic Drug Monitoring, 2022, 44, 301.	2.2	4
3	A Population Physiologically-Based Pharmacokinetic Model to Characterize Antibody Disposition in Pediatrics and Evaluation of the Model Using Infliximab. British Journal of Clinical Pharmacology, 2022, 88, 290-302.	3.0	15
4	Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy. Journal of Pediatrics, 2022, 240, 150-157.e4.	3.2	21
5	Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. Pharmaceutics, 2021, 13, 1821.	7.5	11
6	Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatric Clinics of North America, 2021, 68, 1171-1190.	2.1	14
7	Eculizumab Precision-Dosing Algorithm for Thrombotic Microangiopathy in Children and Young Adults Undergoing HSCT. Blood Advances, 2022, 6, 1454-1463.	6.3	35
8	Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease: Unmet Needs and Future Perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	29.4	169
9	Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease. Gastroenterology, 2022, 162, 1746-1748.e3.	12.5	44
10	Optimizing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Focus on Therapeutic Monoclonal Antibodies. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1423-1431.	4.8	7
11	Antibodies-to-Infliximab Accelerate Clearance While Dose Intensification Reverses Immunogenicity and Recaptures Clinical Response in Paediatric Crohn's Disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 593-603.	7.7	45
12	Population Pharmacokinetics of Nivolumab in Japanese Patients With Nonsmall Cell Lung Cancer. Therapeutic Drug Monitoring, 2023, 45, 110.	2.2	4
13	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 3316.	3.8	11
14	Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1338-1347.	10.5	35
15	Real World Population Pharmacokinetic Study in Children and Young Adults With Inflammatory Bowel Disease Discovers Novel Blood and Stool Microbial Predictors of Vedolizumab Clearance. Alimentary Pharmacology and Therapeutics, 2023, 57, 524-539.	7.7	26
16	Comparison of Short-Term Outcomes for Standard Versus Nonstandard Induction Dosing of Infliximab for Pediatric Inflammatory Bowel Disease. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 732-738.	1.6	1
17	Model-Informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2023, 29, 1342-1346.	5.5	20
18	β-Lactam Precision Dosing in Critically Ill Children: Current State and Knowledge Gaps. Frontiers in Pharmacology, 2022, 13, 1044683.	5.3	18

#	Article	IF	Citations
19	A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-Term Deep Remission in Children With Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2023, 17, 896-908.	8.8	30
20	Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Therapeutic Drug Monitoring, 2023, 45, 143.	2.2	148
21	Editorial: Achievements and Unresolved Questions in Improving the Pharmacokinetics of Vedolizumab in Adolescents With Inflammatory Bowel Disease—Authors' Reply. Alimentary Pharmacology and Therapeutics, 2023, 57, 567-568.	7.7	0
22	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2023, .		0
23	Pursuing Neutrophils: Systematic Scoping Review on Blood-Based Biomarkers as Predictors of Treatment Outcomes in Inflammatory Bowel Disease. Therapeutic Advances in Gastroenterology, 2023, 16, 17562848231155987.	4.2	14
24	Optimization of a Quantitative Anti-Drug Antibodies Against Infliximab Assay With the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives. Pharmaceutics, 2023, 15, 1477.	7.5	9
25	The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America, 2023, 52, 549-563.	3.6	6
26	HLA-DQA1*05 and Upstream Variants of PPARGC1B Are Associated With Infliximab Persistence in Japanese Crohn's Disease Patients. Pharmacogenomics Journal, 2023, 23, 1-8.	3.0	8
27	Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports, 2023, 25, 323-332.	4.9	14
28	Tutorial on Model Selection and Validation of Model Input Into Precision Dosing Software for Model-Informed Precision Dosing. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1827-1845.	3.0	55
29	The Benefit of Early and Frequent Antitumor Necrosis Factor-Alpha Trough Level Determination in Very Early-Onset Inflammatory Bowel Disease. ACG Case Reports Journal, 2023, 10, e01197.	0.8	1
30	Application of a Precision-Dosing Model to a Real-World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis. Journal of Clinical Pharmacology, 2024, 64, 399-409.	2.4	2
31	Drug Clearance in Patients With Inflammatory Bowel Disease Treated With Biologics. Journal of Clinical Medicine, 2023, 12, 7132.	3.8	49
32	Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases, 2024, 30, 1678-1685.	5.5	9
33	De Novo Crohn's Disease Diagnosed in the Setting of Acute SARSCov- 2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics. Journal of Pediatrics Perinatology and Child Health, 2024, 8, 1-4.	0.3	0
34	Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children With Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2024, 63, 529-538.	4.0	11
35	The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model. Paediatric Drugs, 2024, 26, 331-346.	4.6	6
36	Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Paediatric Crohn's Disease (REMODEL-CD): Study Protocol for a Multicentre, Open-Label, Pragmatic Clinical Trial in the USA. BMJ Open, 2024, 14, e077193.	2.7	11

#	Article	IF	Citations
37	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement From the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2024, 46, 291.	2.2	26
38	Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases, 2024, 30, S55-S66.	5.5	7
39	Therapeutic Drug Monitoring and Biomarkers; Towards Better Dosing of Antimicrobial Therapy. Pharmaceutics, 2024, 16, 677.	7.5	7
40	Challenges in IBD Research 2024: Precision Medicine. Inflammatory Bowel Diseases, 2024, 30, S39-S54.	5.5	43
41	Infliximab in Paediatric Inflammatory Bowel Disease: External Evaluation of Population Pharmacokinetic Models. British Journal of Clinical Pharmacology, 2024, 90, 2200-2214.	3.0	5
42	Eicosatetraynoic Acid Regulates Profibrotic Pathways in an Induced Pluripotent Stem Cell–Derived Macrophage-Human Intestinal Organoid Model of Crohn's Disease. Journal of Crohn's and Colitis, 2025, .	8.8	6
43	The Relation Between Inflammatory Biomarkers and Drug Pharmacokinetics in the Critically Ill Patients: A Scoping Review. Critical Care, 2024, 28, 1-19.	9.4	27
44	One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn Disease. Therapeutic Drug Monitoring, 2025, 47, 265.	2.2	3
45	Model-Informed Precision Dosing in Inflammatory Bowel Diseases. Trends in Pharmacological Sciences, 2025, 46, 9-19.	19.8	6
46	Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Paediatric Patients With Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 845.	3.8	6
47	Integrating Early Response Biomarkers in Pharmacokinetic Models: A Novel Method to Individualize the Initial Infliximab Dose in Patients With Crohn's Disease. Clinical and Translational Science, 2025, 18, e70086.	4.1	5
48	Exploring Health Care Professionals' Engagement With a Precision Dosing Calculator and Supporting Clinical Information: Insights From an Eye-Tracking and Usability Study. Therapeutic Drug Monitoring, 2025, 47, 769.	2.2	0
49	Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data. Therapeutic Drug Monitoring, 2026, 48, 10.1097/FTD.0000000000001348.	2.2	9
50	Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2026, 121, 10.14309/ajg.0000000000003521.	5.8	0
51	Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients With COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM). Journal of Clinical Pharmacology, 2025, 65, 1497-1505.	2.4	3
52	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1100-1117.	3.3	22
53	Model-Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models. CPT: Pharmacometrics and Systems Pharmacology, 2025, 14, 1682-1694.	3.0	4
54	A Significant Number of Pediatric Inflammatory Bowel Disease Patients Are Exposed to a Medication Not Approved by the Food and Drug Administration for Pediatric Use. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1208-1215.	3.3	1

#	Article	IF	Citations
55	Hybrid Population Pharmacokinetic–Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn's Disease. Clinical Pharmacokinetics, 2025, 64, 1669-1679.	4.0	12
56	Secondary Loss of Response to Infliximab in Pediatric Crohn's Disease: Real-World Experience in China. Translational Pediatrics, 2025, 14, 2133144-2132144.	1.9	0
57	Population Pharmacokinetics Analysis of Infliximab in Up to 10-Year-Old Patients With Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration. Clinical Pharmacokinetics, 2026, 65, 1-15.	4.0	4
58	Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease. Clinical Pharmacology and Therapeutics, 2026, 119, 555-563.	5.3	6
59	Pharmacokinetics and Exposure–Response During Infliximab Induction Therapy in Pediatric IBD Using Point-of-Care Assay. Journal of Clinical Medicine, 2025, 14, 7968.	3.8	1
60	Building a Beta-Lactam Model-Informed Precision Dosing Service in a Quaternary Care Children's Hospital. Clinical and Translational Science, 2025, 18, e70438.	4.1	5
61	Concentration Monitoring and Dose Optimization for Infliximab in Crohn's Disease Patients: A Machine Learning-Based Covariate Ensemble Model. Frontiers in Immunology, 2025, 16, 1715241.	6.9	3
62	The Coming of Age of Model-Informed Precision Therapeutics for Children. Journal of Pediatric Pharmacology and Therapeutics, 2025, 30, 719-730.	1.6	1
63	Rising Role of Artificial Intelligence in Clinical Pharmacometrics and Model-Informed Precision Dosing in Pediatrics. Journal of Pediatric Pharmacology and Therapeutics, 2026, 31, 106-111.	1.6	1
64	A Methotrexate Dashboard: Integrating MTXPK.org Into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients Receiving High-Dose Methotrexate. JAMIA Open, 2026, 9, ooag057.	5.0	0
65	Multi-Omics Gut Microbiome Signatures for Treat-to-Target Management in Inflammatory Bowel Disease. Microbiological Research, 2026, 309, 128511.	9.9	0
66	Elimination des anticorps monoclonaux par leur cible : étude par modélisation pharmacocinétique. , 0, .		0
67	Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature. Gastro Hep Advances, 2026, 5, 100953.	2.4	0
68	Clinical Model-Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients. Clinical Pharmacology and Therapeutics, 2026, .	5.3	1
69	Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease: Sustained Remission, Predictable Pharmacokinetics, and Real-World US Implementation. Journal of Pediatric Gastroenterology and Nutrition, 2026, .	3.3	4
70	Pharmacometric Targets During Anti-TNF Induction and Their Association With Deep Remission in Pediatric Crohn's Disease. Clinical Pharmacokinetics, 2026, 65, 1353-1365.	4.0	0
71	Evaluation of Pharmacokinetic Metrics and Pharmacodynamic Biomarkers Associated With Endoscopic Healing in Pediatric Crohn's Disease Patients Treated With Anti-Tumor Necrosis Factor Biologics. Crohn's & Colitis 360, 2026, 8, otag088.	2.5	0
72	Population Pharmacokinetics and Pharmacodynamics Under Treatment Evolution, Time-Varying Covariates, Informative Sampling, and Changing Disease State During Clinical Care. International Journal of Pharmaceutical Research and Allied Sciences, 2025, 14, 102-112.	0.9	0

#	Article	IF	Citations
73	Aminosalicylate Use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease. Clinical Gastroenterology and Hepatology, 2026, .	10.5	1
74	Precision Pharmacotherapy Requires Dynamic PKPD Updating After Treatment Begins. International Journal of Pharmaceutical Research and Allied Sciences, 2026, 15, 49-60.	0.9	0